Acetaminophen Toxicity: Symptoms, Causes & Treatment

Acetaminophen (paracetamol, Tylenol) toxicity is the leading cause of acute liver failure in Western countries, responsible for approximately 56,000 emergency visits, 26,000 hospitalizations, and 500 deaths annually in the United States. It is one of the most dangerous 'treacherous' overdoses because early symptoms are deceptively mild — nausea and vomiting only — while hepatocellular necrosis silently escalates over 24–72 hours, peaking on days 3–4.

Therapeutic dosing: 325–1000 mg every 4–6 hours; maximum 4000 mg/day in healthy adults (2000 mg/day with liver disease or chronic alcohol use). Toxic single dose: approximately 7.5–10 g in healthy adults; lower thresholds in chronic alcohol users, malnourished patients, and those on cytochrome P450-inducing medications. The pathophysiological mechanism: acetaminophen is normally conjugated by glucuronidation and sulfation (non-toxic); a small fraction is metabolized via CYP2E1 to N-acetyl-p-benzoquinone imine (NAPQI) — a highly reactive hepatotoxic metabolite that is normally scavenged by hepatic glutathione. In overdose, glutathione is depleted, NAPQI accumulates, and causes centrilobular hepatocellular necrosis.

The antidote — N-acetylcysteine (NAC) — replenishes glutathione stores and neutralizes NAPQI. NAC administered within 8–10 hours of ingestion achieves near-complete hepatoprotection (>95% prevention of significant liver injury). Efficacy falls sharply after 16 hours; benefit still exists up to 24 hours. Beyond 24 hours with established hepatotoxicity, NAC continues to reduce mortality but cannot reverse established necrosis.

• Phase 1 (0–24 hours): nausea, vomiting, malaise, anorexia — or may be asymptomatic; patient typically feels 'not that sick'
• Phase 2 (24–72 hours): RUQ tenderness, elevated AST/ALT (may exceed 10,000 IU/L), elevated INR; subjective improvement may falsely reassure patient
• Phase 3 (72–96 hours): peak hepatotoxicity — jaundice, coagulopathy (INR >1.5), acute kidney injury (hepatorenal), hepatic encephalopathy, hypoglycemia, metabolic acidosis; multi-organ failure in severe cases
• Phase 4 (>96 hours): full recovery of hepatic function in most treated patients; progression to liver transplantation or death in untreated severe cases

• Intentional overdose (suicide attempt or self-harm): the most common cause in Western countries
• Unintentional staggered overdose: taking multiple acetaminophen-containing products concurrently (combination cold medicines + OTC analgesics + prescription narcotics with APAP) — often unrecognized
• Chronic alcohol use: induces CYP2E1 (more NAPQI production) and depletes glutathione — toxic at lower-than-usual doses; alcoholic hepatitis alone does not reliably increase risk at therapeutic doses
• Malnutrition and fasting: depletes glutathione stores, reducing the protective buffer against NAPQI
• Enzyme-inducing medications: rifampicin, carbamazepine, phenytoin, phenobarbital — upregulate CYP2E1

Serum acetaminophen level at ≥4 hours post-ingestion: plot on the Rumack-Matthew nomogram to determine NAC treatment threshold (above 'treatment line' = treat). AST, ALT, INR, bilirubin, creatinine, blood glucose: assess hepatotoxicity severity. In staggered overdose (multiple doses over time): nomogram not applicable — treat based on clinical risk and LFTs. King's College Criteria: identifies patients requiring liver transplantation (pH <7.3, INR >6.5, creatinine >300 µmol/L, grade III-IV encephalopathy).

N-acetylcysteine (NAC): the definitive antidote — replenishes glutathione and scavenges NAPQI. IV protocol: 150 mg/kg over 1 hour (loading), then 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours (total 21-hour Prescott regimen). Oral alternative: 140 mg/kg loading, then 70 mg/kg every 4 hours × 17 doses. Activated charcoal (1 g/kg): administer within 1 hour of ingestion — reduces absorption by 50–70%. Gastric lavage: limited benefit if >1 hour post-ingestion. Supportive care: IV glucose for hypoglycemia, FFP for coagulopathy with bleeding, hemodialysis for renal failure. Liver transplantation: for irreversible acute liver failure (King's College Criteria); must be listed before encephalopathy becomes refractory.

• Acute liver failure: coagulopathy, hepatic encephalopathy, cerebral edema — the main cause of death
• Acute kidney injury in ~25% of severe cases — from direct nephrotoxicity and hepatorenal syndrome
• Death without treatment or transplantation in 1–5% of all hospitalizations; much higher in untreated severe late-presenting cases

• Do not exceed 4000 mg/day (healthy adults) or 2000 mg/day (liver disease, chronic alcohol use)
• Read all medication labels — many combination products (cold medicines, sleep aids, prescription opioids) contain acetaminophen: double-dosing is a common unintentional cause
• Secure storage away from children and individuals at risk of self-harm
• Pack size limitation (≤96 tablets per pharmacy purchase): evidence-based policy that significantly reduces acetaminophen overdose mortality in the UK